TATA Health International Holdings Limited (Stock code: 1255) announced that, effective 21 October 2025, a non-executive Director was re-designated as an executive Director and installed as Chief Executive Officer, alongside the appointment of a new Chief Financial Officer.

According to the announcement, Mr. Zhang Ming Qi, aged 32, has been re-designated from non-executive Director to executive Director and appointed as Chief Executive Officer. He has experience ranging from investment banking to financial advisory, including roles at C.V. Starr & Co., Inc. and Beijing Hande Donghui Asset Management Co., Ltd. Mr. Zhang holds an undergraduate degree from the University of Wisconsin-Madison and a master’s degree from Boston University Questrom School of Business. He entered into a new service contract for a three-year term from 23 June 2025, with a monthly director’s fee of HK$100,000, and an employment contract for the CEO role that includes a monthly salary of HK$100,000 plus discretionary bonuses.

Also effective 21 October 2025, Mr. Che Kean Tat, aged 42, will serve as Chief Financial Officer. He has over two decades of professional expertise in accounting, auditing, corporate finance, and IPO advisory, having worked in firms such as Ernst & Young LLP and Auscar Wealth Management Sdn Bhd. Most recently, he held senior roles at Nova Group Holdings Limited and other listed entities. Mr. Che is entitled to a monthly salary of HK$100,000. He is a member of CPA Australia and graduated from the University of Adelaide with a major in Accounting and Finance.